Correlation between vitamin D and thyroid disease

doi:10.12092/j.issn.1009-2501.2020.01.014

Abstract

Abstract: In addition to the role of vitamin D in regulating calcium and phosphorus homeostasis and bone metabolism, immune regulation and anti-tumor proliferation have been gradually proposed by researchers. At present, a large number of studies have found that patients with thyroid diseases have low vitamin D levels, and it is believed that vitamin D insufficiency/ deficiency may be involved in the pathogenesis of thyroid diseases, but the specific relationship and mechanism between vitamin D and thyroid diseases have not been fully clarified. This article reviewed in the relationship between vitamin D and several common thyroid diseases in recent years, in order to analyze the role of vitamin D in the pathogenesis of thyroid diseases, as well as the influence of vitamin D supplementation on the occurrence and development of thyroid diseases.

Key words: vitamin D, Graves' disease, Hashimoto's thyroiditis, thyroid nodules, thyroid cancer

CLC Number:

R581

SU Shan, ZHANG Di, WANG Qiangmei, ZHEN Donghu. Correlation between vitamin D and thyroid disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 94-100.

References

［1］Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention［J］. Rev Endocr Metab Disord, 2017, 18(2):153-165.
［2］Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications［J］. Chem Biol,2014,21(3):319-329.
［3］Incel Uysal P, Alli N, Hayran Y, et al. Mycosis fungoides and vitamin D status: Analyses of serum 25-hidroxyvitamin D levels and single nucleotide polymorphisms in the vitamin D receptor gene［J］. Acta dermatovenerologica Croatica, 2018, 26(1): 8.
［4］Gil , Plaza-Diaz J, Mesa MD. Vitamin D: Classic and novel actions［J］. Ann Nutr Metab, 2018,72(2):87-95.
［5］Eshaghkhani Y, Sanati MH, Nakhjavani M, et al. Disturbed Th1 and Th2 balance in patients with Graves' disease［J］. Minerva Endocrinol, 2016, 41(1):28-36.
［6］Berg JP, Ree AH, Sandvik JA, et al. 1,25-dihydroxyvitamin D3 alters the effect of cAMP in thyroid cells by increasing the regulatory subunit type II beta of the cAMP-dependent protein kinase［J］. J Biol Chem,1994,269(51):32233-32238.
［7］Sheikh V, Kasapoglu P, Zamani A, et al. Vitamin D3 inhibits the proliferation of T helper cells, downregulate CD4+T cell cytokines and upregulate inhibitory markers［J］. Hum Immunol, 2018,79(6):439-445.
［8］Prietl B, Treiber G, Pieber T, et al. Vitamin D and immune function［J］. Nutrients,2013,5(7):2502-2521.
［9］Corripiomiyar Y, Mellanby R J, Morrison K, et al. 1,25-Dihydroxyvitamin D3 modulates the phenotype and function of monocyte derived dendritic cells in cattle［J］. BMC Vet Res,2017,13(1):390.
［10］Misharin A, Hewison M, Chen CR, et al. Vitamin D deficiency modulates graves' hyperthyroidism induced in BALB/c mice by thyrotropin receptor immunization［J］. Endocrinology,2009,150(2):1051-1060.
［11］Yasuda T，Miyashita K，Takahara M，et al. Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves disease［J］. Endocrine，2012,42(3):739-741.
［12］Yasuda T，Miyashita K，Takahara M，et al. Serum vitamin D levels are decreased in patients without remission of Graves'disease ［J］. Endocrine,2013,43(1):230-232.
［13］Mangaraj S, Choudhury AK, Swain BM, et al. Evaluation of vitamin D status and its impact on thyroid related parameters in new onset Graves' disease-A cross-sectional observational study［J］. Indian J Endocrinol Metab. 2019,23(1):35-39.
［14］Li X, Wang G, Lu Z, et al. Serum 25-hydroxyvitamin D predict prognosis in radioiodine therapy of Graves' disease［J］. J Endocrinol Invest, 2015, 38(7):753-759.
［15］Kawakamitani T, Fukawa E, Tanaka H, et al. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease［J］. Metabolism,1977,46(10):1184-1188.
［16］Planck T, Shahida B, Malm J, et al. Vitamin D in Graves disease: Levels, correlation with laboratory and clinical parameters, and genetics［J］. Eur Thyroid J, 2018,7(1):27-33.
［17］Safdari V, Alijani E, Nemati M, et al. Imbalances in T cell-related transcription factors among patients with Hashimoto's thyroiditis［J］. Sultan Qaboos Univ Med J,2017,17(2): 174-180.
［18］tefanic M, Tokic S. Serum 25-hydoxyvitamin D concentrations in relation to Hashimoto's thyroiditis: a systematic review, meta-analysis and meta-regression of observational studies［J］.Eur J Nutr,2019,1-14.
［19］Ucan B, Sahin M, Arslan MS, et al. Vitamin D treatment in patients with Hashimoto's thyroiditis may decrease the development of hypothyroidism［J］. Int J Vitam Nutr Res, 2017, 86(1-2):1-9.
［20］刘杉,熊丰,刘恩梅,等.1，25(OH)2D3干预实验性自身免疫性甲状腺炎TH1/TH2细胞失衡的研究［J］.南方医科大学学报,2010,30(7):1573-1576.
［21］Vahabi PA, Aminorroaya A, Amini M, et al. Effect of vitamin D deficiency treatment on thyroid function and autoimmunity markers in Hashimoto's thyroiditis: A double-blind randomized placebo-controlled clinical trial［J］. J Res Med Sci, 2017, 22(1):103.
［22］刘茂,王培桦.甲状腺结节影响因素分析［J］.江苏预防医学,2017,28(6):665-667.
［23］Du X, Liu Y, Zhao C, et al. Changes of serum 25(OH) D3 and IGF-1 levels in patients with thyroid nodules［J］. BMC Endocr Disord, 2019, 19(1):48.
［24］王广利, 谭运新. 甲状腺结节患者血清维生素D水平的检测及意义［J］. 世界最新医学信息文摘,2018,18(78):94-99.
［25］闫艳芳. 雌、雄激素和维生素D及其受体在甲状腺结节患者血清及甲状腺组织中的水平［D］. 河北医科大学，2015.
［26］Figge, JJ. Epidemiology of thyroid cancer［M］. New York: Springer, 2016.
［27］Li M, Li L, Zhang L, et al. 1,25-Dihydroxyvitamin D3, suppresses gastric cancer cell growth through VDR- and mutant p53-mediated induction of p21［J］. Life Sci, 2017,179:88-97.
［28］Bandera MB, Morcillo S, MartinNunez G, et al. The role of vitamin D and VDR in carcinogenesis: Through epidemiology and basic sciences［J］. J Steroid Biochem Mol Biol, 2017, 167:203-218.
［29］Penna MM, Ramos LE, Stern J, et al. Vitamin D receptor polymorphisms in differentiated thyroid carcinoma［J］. Carcinogenesis,2009,30(7):1170-1180.
［30］Zhao JY,Wang HP,Zhang ZW, et al. Vitamin D deficiency as a risk factor for thyroid cancer: A meta-analysis of case-control studies［J］. Nutrition, 2019,57:5-11.
［31］Chiang KC, Kuo SF, Chen CH, et al. MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential［J］. Cancer Lett, 2015, 369(1):76-85.
［32］Zhang T, Zhang H, He L, et al. Potential use of 1-25-dihydroxyvitamin D in the diagnosis and treatment of papillary thyroid cancer［J］. Med Sci Monit, 2018, 24:1614-1623.
［33］Ahn HY, Chung YJ, Park KY，et al. Serum 25-hydroxyvitamin D level does not affect the progressiveness and prognosis of papillary thyroid cancer［J］. Thyroid, 2016, 26(3):429-433.

[1]	XIE Jingjing, YIN Hongtao, LIU Jinjin, SUN Weiming, ZHEN Donghu. Baseline serum 25-hydroxyvitamin D3 levels and risk of metabolic syndrome: a prospective cohort study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 641-652.
[2]	ZHANG Wei, LIU Lei, GUAN Shaoyang, SHENG Zhao, SUN Wenwen. Analysis of the diagnostic value of fine-needle aspiration cytology and BRAF and RAS gene mutation screening for thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 653-657.
[3]	BAI Jia, YANG Hong, LI Lingling, ZHANG Yangyang, YANG Ying, LV Haihong. Study on the effect of vitamin D on diabetic neuropathy through mitochondrial/autophagy pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 214-219.
[4]	LI Chenhao, YU Xihua, YAN Wenhao, CHAI Yuxia, LI Yanyan, LI Kun, LI Zeyun. Research progress on the relationship between pediatric epilepsy and vitamin D [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1299-1306.
[5]	TANG Jiawei, MENG Xiangzhe, SUN Xuemin, LI Yuexuan, LIU Xue, WEI Hong. Role of vitamin D and ACE2 in COVID-19 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1292-1298.
[6]	CHEN Wenjie, WANG Yabing, CHEN Xiaolin, REN Junling, ZHAO Wanjun, CHEN bin. Advances in the study of iodine-resistant differentiated thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 116-120.
[7]	ZHANG Quan, SHI Shiyuan, HAN Guihe. 1,25 dihydroxy vitamin D3 for immunoregulation in the treatment of spinal tuberculosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 787-793.
[8]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[9]	LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa. Relevance of CYP2R1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
[10]	TANG Xinyue, SHI Feng, LI Cuilin, LIU Jianqiu, LI Zhi. Research progress of TERT promoter mutation in thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 350-354.
[11]	WANG Ping, XU Xiao-jing, BU Feng-xiao, ZHOU Yu, YE An, ZHOU Bo-ting. SNP rs1024750 polymorphism in the EGFR gene significantly influences serum calcium levels in postmenopausal Caucasian women [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 772-779.
[12]	LI Dong, XIA Chen-mei, CHEN Xia, YAN Hai-fan, FENG Chong-zhi. Effects of calcitriol on bone mineral density and bone metabolic markers in male patients with alcoholic cirrhosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 691-694.
[13]	PAN Hai, LIU Jin-xin, ZHANG Yan. Pathogenesis, clinical diagnosis and treatment for CKD-MBD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 695-700.
[14]	MENG Xiang-guang, LI Zhi, WANG Xian-meng, ZHOU Hong-hao. Advances in Pharmacogenetics of Topical Therapies for Psoriasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1179-1184.
[15]	ZHANG Xia-juan, BAO Li-fang, BAO Zhou-jun, WANG Yin, LI Yi-wei, WANG Ye-kai. Dosage research of serum 25-hydroxyvitamin D levels on different intervention treatments for children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(12): 1419-1422.